EMA aldosterone synthase inhibitor coverage for business development, investment, and market access teams
The FDA's recent approval of a first-in-class aldosterone synthase inhibitor marks a significant advancement in treating uncontrolled hypertension, with implications for investors and pharma teams.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
